PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic Journal

Archives of Women's Mental Health

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

Archives of Women's Mental Health has 1 tracked paper indexed in Blossom (2022) from 7 authors, most often covering Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).

Published Papers

Open Accessindividual

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Pooled analyses of three short-term randomised controlled trials found that esketamine nasal spray plus a newly initiated oral antidepressant produced greater reductions in MADRS total score than antidepressant plus placebo in both women and men with treatment‑resistant depression, with no significant sex effect or treatment-by-sex interaction. Overall safety was similar between sexes, although nausea, dissociation, dizziness and vertigo were reported more frequently in women.

Published
January 1, 2022
Journal
Archives of Women's Mental Health
Authors
Jones, R. R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E. J., Canuso, C. M., Nicholson, S.

Quick Facts

Papers Indexed
1
h-Index
104
Open Access
No
Publisher
Springer Nature
Country
Austria
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.